Akoya Biosciences, Inc. (NASDAQ:AKYA) Q2 2024 Earnings Call Transcript
Akoya Biosciences, Inc. (NASDAQ:AKYA) Q2 2024 Earnings Call Transcript August 5, 2024Akoya Biosciences, Inc. reports earnings inline with expectations.
Akoya Biosciences Inc. (AKYA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Parkman Healthcare Partners Greg Martinez | 375,536 | $878,754 | -60% | 0.11% |
| 2. | Polar Capital Brian Ashford-Russell And Tim Woolley | 329,756 | $771,629 | -80% | 0% |
| 3. | Schonfeld Strategic Advisors Ryan Tolkin (Cio) | 294,342 | $688,760 | -22% | 0% |
| 4. | Osterweis Capital Management John Osterweis | 126,131 | $295,147 | 0.01% | |
| 5. | Renaissance Technologies Jim Simons | 22,200 | $51,948 | -57% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.60 | 7,000 | Officer | 20,000 | 2023-09-07 | Filing | |
| $4.60 | 13,000 | Officer | 13,000 | 2023-09-07 | Filing | |
| $5.00 | 20,000 | Officer | 20,000 | 2023-06-12 | Filing | |
| $5.00 | 20,000 | Director | 20,000 | 2023-06-12 | Filing | |
| $5.00 | 20,000 | Director | 28,500 | 2023-06-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.08 | 7,500 | Officer, Director | 224,733 | 2024-06-11 | Filing | |
| $2.01 | 7,500 | Officer, Director | 224,733 | 2024-06-06 | Filing | |
| $4.97 | 7,500 | Officer, Director | 231,868 | 2024-03-20 | Filing | |
| $4.94 | 7,500 | Officer, Director | 231,868 | 2024-03-13 | Filing | |
| $4.94 | 7,500 | Officer, Director | 224,368 | 2024-03-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,697,785 | $22,925,191 | 20.08% | |
| 2. | 1,408,157 | $6,871,807 | 0% | |
| 3. | 1,372,232 | $6,696,492 | 0% | |
| 4. | 620,433 | $3,027,712 | 0.19% | |
| 5. | 515,317 | $2,514,747 | 0.06% |
News See All
Akoya Biosciences, Inc. (NASDAQ:AKYA) Q1 2024 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Akoya Biosciences First Quarter 2024 Earnings Conference Call. All this time all participants are in a listen-only mode.
Akoya Biosciences, Inc. (NASDAQ:AKYA) Q4 2023 Earnings Call Transcript
Akoya Biosciences, Inc. beats earnings expectations. Reported EPS is $-0.22, expectations were $-0.27.
Akoya Biosciences, Inc. (NASDAQ:AKYA) Q3 2023 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Akoya Biosciences Incorporated Third Quarter 2023 Earnings Conference Call.
10 Healthcare Stocks with Insider Buying
Investors were processing inflation report on August 10 to find clues on the Federal Reserve’s possible moves. CPI’s growth in July was identical to that of June’s.
Akoya Biosciences, Inc. (NASDAQ:AKYA) Q2 2023 Earnings Call Transcript
Operator: Good day and welcome to the Akoya Biosciences Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Hedge Fund and Insider Trading News: Crispin Odey, George Soros, Cathie Wood, Arex Capital Management, Akoya Biosciences Inc (AKYA), Satsuma Pharmaceuticals, Inc. (STSA), and More
Hedge fund Arex Capital Management is urging Enhabit (EHAB.N) to put itself up for sale and wants the home health and hospice provider to begin a strategic review to help reverse a 50% slide in its share...
Akoya Biosciences, Inc. (NASDAQ:AKYA) Q1 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Akoya Biosciences First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Akoya Biosciences, Inc. (NASDAQ:AKYA) Q4 2022 Earnings Call Transcript
Operator: Thank you for standing by. And welcome to the Akoya Biosciences Fourth Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Small Caps Begin to Rebound: 10 Stocks to Buy Now
Carter Worth, the CEO of Worth Charting, joined CNBC’s ‘The Exchange’ on August 10 to review the energy sector and the recent outperformance of small-cap stocks over large-caps.
Billionaire Hedge Funds
